We are primarily focused on the improvement and optimization of natural products as potential therapeutic options for patients with chronic disorders that do not respond well to traditional pharmaceuticals.
Traditional medicine has been undervalued and we aim to explore the safety and efficacy of novel secondary metabolites present in traditional methods, including complex herbal extractions produced in both formulations for oral administration and smoking.
Our team wants to develop the most eco-friendly and efficient means for producing these products without the use of toxic chemicals or the creation of unnecessary byproducts.
We are pursuing research to better understand variations in therapeutic profiles of traditional medicines. We are looking beyond individual "active" secondary metabolites and into specific formulations including rare, often overlooked compounds.
We have developed a patent-pending dual extraction/processing method to create novel extractions using natural products. This method is simple, safe, eco-friendly, and uses a fraction of reagent materials as traditional methods.
There is a large diversity of formulations that can be produced using our patent-pending method. These formulations are unique and will create a different therapeutic profile than the starting material or from traditional methods of extraction.
When two compounds interact to form a larger therapeutic effect than would be expected separately, they are called synergistic. Most negative side effects are a result of having large doses present in the body (overloading target systems or interacting with off-targets at high concentrations); synergy by formulation allows the total dosage to be reduced while maintaining the desired therapeutic effect.
Real Isolates Founders and Co-Inventors of Smokenol™
Our research is founded upon our own personal desire to bring validity to natural products that help us manage our symptoms.
"Cannabis saved my life. I believe in the molecular basis of Cannabis as a valid therapeutic option for chronic neurological, inflammatory, and autoimmune disorders."
Dr. Shields is a biochemist who specializes in the endocannabinoid system (ECS); their research began in 2010, the same year they received their prescription in medical Cannabis. From 2010-2012 they evaluated drugs that act downstream of the ECS in animal models at UC Davis. From 2012-2018 they pursued their PhD at Northeastern University investigating synthetic cannabinoids for the treatment of opioid addiction, but the phytocannabinoids always remained their core interest.
"Since I was very young, I have lived with symptoms that impacted my quality of life. At age 25 I was officially diagnosed with a rare neurological disorder with no treatment options."
After attending Clemson University and graduating from the University of Massachusetts Manning School of Business, Andrew put his efforts into early-stage startup companies. Today, he lives with multiple autoimmune disorders, including HNPP, a rare disease in which nerves are slowly and progressively destroyed by the body's immune system. After his wife was diagnosed with multiple autoimmune disorders he began cultivating Cannabis. The improvement he saw in both himself and his wife influenced him to pursue a career in improving Cannabis products.